• Rewiring HIF-1α Research with Octyl-α-ketoglutarate

  2026-08-23

  A mechanistic and translational framework for using Octyl-α-ketoglutarate to test how α-ketoglutarate availability, IDH-driven metabolic rewiring, and prolyl hydroxylase activity converge on HIF-1α regulation.

• TP53-Dependent DHODH Inhibition in NPC

  2026-08-22

  Dong et al. identify pyrimidine biosynthesis and DHODH as metabolically relevant vulnerabilities in nasopharyngeal carcinoma (NPC), combining multi-dataset analysis with pharmacological and genetic validation. Their results show that BAY2402234 suppresses NPC cell growth and invasive behavior through a mechanism substantially dependent on TP53 signaling, while also defining important considerations for translating metabolic findings into protein-level assays.

• Sulfamonomethoxine: Applied Research Workflows

  2026-08-21

  Sulfamonomethoxine supports controlled antimicrobial, aquaculture, and environmental fate studies through a defined DHPS mechanism and flexible solvent-based preparation. This workflow guide shows how to separate true biotransformation from sorption, improve assay reproducibility, and troubleshoot matrix effects without turning laboratory findings into unsupported field-dosing advice.

• Sulfamonomethoxine: From Use to Environmental Fate

  2026-08-21

  Sulfamonomethoxine (SMM) is examined here through a mass-balance lens that connects DHPS inhibition with adsorption, biotransformation, and aquatic risk. The article translates aerobic granular sludge evidence into practical controls for veterinary, aquaculture, and environmental assays.

• PR-619: Deubiquitylating Enzymes Inhibitor

  2026-08-20

  PR-619 is a reversible, cell-permeable deubiquitylating enzymes inhibitor that broadly targets cysteine-dependent DUBs. It increases intracellular ubiquitinated proteins without directly inhibiting proteasomal catalytic activity, making it useful for ubiquitination pathway research, autophagy assays, cancer biology research, and neurodegeneration studies.

• FOXO3/YAP Metabolic Control in HCC

  2026-08-20

  The reference study identifies FOXO3 as a tumor-suppressive regulator that simultaneously restrains glycolysis and glutaminolysis in hepatocellular carcinoma through direct repression of YAP. Its combination of promoter-level mechanistic analysis, pharmacological validation, animal experiments, and patient-derived organoids supports the FOXO3/YAP axis as a candidate framework for overcoming metabolic compensation in HCC.

• BHQ: A Mechanistic Tool for SERCA–Ca2+ Studies

  2026-08-19

  Explore how 2,5-di-tert-butylbenzene-1,4-diol (BHQ) converts SERCA inhibition into a controlled probe of calcium signaling, ER stress, and cell-state transitions. This guide emphasizes assay interpretation, experimental controls, and the translational limits of connecting calcium homeostasis disruption with HSC mobilization.

• AS1842856 Foxo1 Inhibitor Workflow Guide

  2026-08-19

  AS1842856 enables researchers to separate Foxo1 activity from Foxo1 abundance in gluconeogenesis, autophagy, and PI3K-Akt-Foxo1 studies. This practical guide combines hepatic metabolic assays with a cautious, pathway-informed workflow for exploring mesenchymal stem cell activation.

• Mixed-Dimensional Attapulgite Clay for Hemostasis

  2026-08-18

  This study shows that natural mixed-dimensional attapulgite clay can achieve rapid hemostasis through the coordinated effects of its one-dimensional and two-dimensional mineral components. Oxalic-acid treatment tuned the clay structure, surface properties, platelet response, and coagulation performance, providing a mechanistic basis for developing inorganic hemostatic materials from naturally occurring mixed clays.

• Sulfachloropyridazine: DHPS Mechanism and Research Use

  2026-08-18

  Sulfachloropyridazine is a sulfonamide antibacterial agent that competitively inhibits dihydropteroate synthase and disrupts bacterial folate synthesis. Research applications include enzyme inhibition assay design, antimicrobial susceptibility testing, microbial ecology studies, and carefully controlled infection models.

• E-64d and Death-Rate-Resolved Cell Assays

  2026-08-17

  E-64d is a membrane-permeable cysteine protease inhibitor that can expose how intracellular protease activity shapes cell survival. This article connects E-64d perturbation with death-rate-resolved functional genomics, offering a more rigorous framework for apoptosis, platelet, neuroprotection, and cancer research.

• PBS Liposomes: Macrophage Depletion Controls

  2026-08-16

  PBS Liposomes (K2722) are phosphate-buffered saline liposomes designed as a negative control for macrophage depletion experiments. Their blank formulation separates effects caused by liposome uptake from effects caused by clodronate-mediated macrophage depletion.

• Entecavir in Decompensated Chronic Hepatitis B

  2026-08-15

  Keating’s 2011 review synthesized pharmacology, pharmacokinetics, clinical efficacy, and tolerability data for Entecavir in patients with chronic hepatitis B and decompensated liver disease. Its main contribution was to place potent viral suppression and a high resistance barrier in the context of a medically fragile population, while emphasizing renal dosing, safety surveillance, and the limits of largely nonrandomized evidence.

• Plant Cell Lysis Buffer for WB and IP: Assay Workflows

  2026-08-15

  Build reliable native protein workflows for plant tissues, protoplasts, and compatible cross-kingdom samples using a Triton X-100-based inhibitor system. This guide connects practical Western blotting, immunoprecipitation, and co-IP decisions with mechanistic insights from the MAPK10–KRT16 cancer study.

• Ionophore Toxicity: Molecular and Clinical Insights

  2026-08-14

  The 2023 review by Ekinci, Chłodowska, and Olejnik connects clinical ionophore poisoning in animals with membrane ion transport, mitochondrial dysfunction, and muscle injury. Its main practical contribution is a framework for interpreting toxicity according to dose, species, age, drug interactions, and molecular endpoints while assessing the translational limits of ionophores such as salinomycin.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page